![]() ![]() It is meant to speed their clinical development, regulatory review - enabling a rolling review - and, if approved, their entry into the market. This designation is given to therapies that show considerable potential in addressing serious conditions for which available treatments fall short. ![]() Food and Drug Administration (FDA) has given fast track designation to RedHill Biopharma’s RHB-204 as a potential first-line and stand-alone, oral treatment for lung infections caused by Mycobacterium avium complex (MAC), a type of non-tuberculous mycobacteria (NTM). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2022
Categories |